Compare AstraZeneca plc (AZN) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.29. The key difference: AstraZeneca plc pays a 2.01% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | NVDL | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $43.02 |
52-Week Low | $147.06 | $21.76 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.40, up 5.94% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to NVIDIA's AI-driven growth, though recent performance has trailed NVDA's gains. Technical indicators show mixed signals with overbought RSI levels but strong trend momentum from ADX readings.
The outlook remains tied to NVIDIA's AI leadership and upcoming earnings, offering amplified returns but with significant volatility risk from daily reset leverage. Key risks include NVDA's valuation sensitivity and leverage decay during choppy markets, requiring careful risk management for investors seeking aggressive NVDA exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
